Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial D Athauda, K Maclagan, SS Skene, M Bajwa-Joseph, D Letchford, ... The Lancet 390 (10103), 1664-1675, 2017 | 670 | 2017 |
Exenatide and the treatment of patients with Parkinson’s disease I Aviles-Olmos, J Dickson, Z Kefalopoulou, A Djamshidian, P Ell, ... The Journal of clinical investigation 123 (6), 2730-2736, 2013 | 467 | 2013 |
Parkinson's disease, insulin resistance and novel agents of neuroprotection I Aviles-Olmos, P Limousin, A Lees, T Foltynie Brain 136 (2), 374-384, 2013 | 302 | 2013 |
MRI-guided STN DBS in Parkinson's disease without microelectrode recording: efficacy and safety T Foltynie, L Zrinzo, I Martinez-Torres, E Tripoliti, E Petersen, E Holl, ... Journal of Neurology, Neurosurgery & Psychiatry 82 (4), 358-363, 2011 | 288 | 2011 |
Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson’s disease I Aviles-Olmos, J Dickson, Z Kefalopoulou, A Djamshidian, J Kahan, P Ell, ... Journal of Parkinson's disease 4 (3), 337-344, 2014 | 287 | 2014 |
Which patients with dystonia benefit from deep brain stimulation? A metaregression of individual patient outcomes C Andrews, I Aviles-Olmos, M Hariz, T Foltynie Journal of Neurology, Neurosurgery & Psychiatry 81 (12), 1383-1389, 2010 | 235 | 2010 |
Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson's disease using an MRI-guided and MRI-verified approach I Aviles-Olmos, Z Kefalopoulou, E Tripoliti, J Candelario, H Akram, ... Journal of Neurology, Neurosurgery & Psychiatry 85 (12), 1419-1425, 2014 | 197 | 2014 |
A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease RA Scott, DF Freitag, L Li, AY Chu, P Surendran, R Young, N Grarup, ... Science translational medicine 8 (341), 341ra76-341ra76, 2016 | 124 | 2016 |
Deep brain stimulation for Gilles de la Tourette syndrome: a case series targeting subregions of the globus pallidus internus R Martínez‐Fernández, L Zrinzo, I Aviles‐Olmos, M Hariz, ... Movement disorders 26 (10), 1922-1930, 2011 | 120 | 2011 |
Differences in MDS‐UPDRS scores based on Hoehn and Yahr stage and disease duration M Skorvanek, P Martinez‐Martin, N Kovacs, M Rodriguez‐Violante, ... Movement disorders clinical practice 4 (4), 536-544, 2017 | 111 | 2017 |
Decision making, impulsivity, and addictions: do Parkinson's disease patients jump to conclusions? A Djamshidian, SS O'Sullivan, Y Sanotsky, S Sharman, Y Matviyenko, ... Movement disorders 27 (9), 1137-1145, 2012 | 110 | 2012 |
Predictive factors of speech intelligibility following subthalamic nucleus stimulation in consecutive patients with Parkinson's disease E Tripoliti, P Limousin, T Foltynie, J Candelario, I Aviles‐Olmos, MI Hariz, ... Movement Disorders 29 (4), 532-538, 2014 | 107 | 2014 |
Genotype and phenotype in Parkinson's disease: lessons in heterogeneity from deep brain stimulation A Angeli, NE Mencacci, R Duran, I Aviles‐Olmos, Z Kefalopoulou, ... Movement Disorders 28 (10), 1370-1375, 2013 | 100 | 2013 |
MRI-guided subthalamic nucleus deep brain stimulation without microelectrode recording: can we dispense with surgery under local anaesthesia? T Nakajima, L Zrinzo, T Foltynie, IA Olmos, C Taylor, MI Hariz, P Limousin Stereotactic and functional neurosurgery 89 (5), 318-325, 2011 | 97 | 2011 |
Relationship between the MDS-UPDRS and quality of life: a large multicenter study of 3206 patients M Skorvanek, P Martinez-Martin, N Kovacs, I Zezula, ... Parkinsonism & related disorders 52, 83-89, 2018 | 70 | 2018 |
What effects might exenatide have on non-motor symptoms in Parkinson’s disease: a post hoc analysis D Athauda, K Maclagan, N Budnik, L Zampedri, S Hibbert, SS Skene, ... Journal of Parkinson's disease 8 (2), 247-258, 2018 | 62 | 2018 |
Time to consider the “exposome hypothesis” in the development of the obesity pandemic V Catalán, I Avilés-Olmos, A Rodríguez, S Becerril, ... Nutrients 14 (8), 1597, 2022 | 58 | 2022 |
Short and long term outcome of bilateral pallidal stimulation in chorea-acanthocytosis M Miquel, U Spampinato, C Latxague, I Aviles-Olmos, B Bader, K Bertram, ... PLoS One 8 (11), e79241, 2013 | 58 | 2013 |
Post hoc analysis of the Exenatide‐PD trial—factors that predict response D Athauda, K Maclagan, N Budnik, L Zampedri, S Hibbert, I Aviles‐Olmos, ... European Journal of Neuroscience 49 (3), 410-421, 2019 | 57 | 2019 |
Gender differences in quality of life following subthalamic stimulation for P arkinson's disease GM Hariz, P Limousin, L Zrinzo, E Tripoliti, I Aviles‐Olmos, M Jahanshahi, ... Acta Neurologica Scandinavica 128 (4), 281-285, 2013 | 50 | 2013 |